Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCAR-G08

Cell therapy (CAR-T) · Kills target cells, directed at guanylyl cyclase C (GUCY2C)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is LCAR-G08?

LCAR-G08 is an autologous T-lymphocyte preparation genetically engineered with a lentiviral vector to express a chimeric antigen receptor targeting guanylyl cyclase C (GUCY2C), an enterocyte differentiation antigen overexpressed on various tumor cells. The engineered cells are directed to GCC-expressing tumor cells, where they activate, proliferate and release cytokines to kill them. It is being studied in advanced gastrointestinal tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
guanylyl cyclase C (GUCY2C) (antigen)
Mechanism
Kills target cells, directed at guanylyl cyclase C (GUCY2C)
Therapy area
Oncology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06197178 Phase 1 Advanced Gastrointestinal Tumors Terminated LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Gastrointestinal Tumors

Other drugs acting on GUCY2C

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.